Literature DB >> 2245211

Orientation into the lipid bilayer of an asymmetric amphipathic helical peptide located at the N-terminus of viral fusion proteins.

R Brasseur1, M Vandenbranden, B Cornet, A Burny, J M Ruysschaert.   

Abstract

The complete amino-acid sequence of viral fusion proteins has been analyzed by the Eisenberg procedure. The region surrounding the cleavage site contains a highly hydrophilic region immediately followed by a membrane-like region. Since the effective cleavage between these two domains seems required to expose the fusogenic domain (located at the N-terminal sequence of the transmembrane like region) which is assumed to interact with the lipid membrane of the host cell, we have focused our analysis on the conformation and mode of insertion of this membrane-like domain in a lipid monolayer. It was inserted as an alpha-helical structure into a dipalmitoylphosphatidylcholine (DPPC) monolayer and its orientation at the lipid/water interface was determined using a theoretical analysis procedure allowing the assembly of membrane components. For each viral protein sequence these N-terminal helical segments oriented obliquely with respect to the lipid/water interface. This rather unusual orientation is envisaged as a prerequisite to membrane destabilization and fusogenic activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2245211     DOI: 10.1016/0005-2736(90)90163-i

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  21 in total

1.  Implicit solvent model studies of the interactions of the influenza hemagglutinin fusion peptide with lipid bilayers.

Authors:  D Bechor; N Ben-Tal
Journal:  Biophys J       Date:  2001-02       Impact factor: 4.033

2.  Conformational partitioning of the fusion peptide of HIV-1 gp41 and its structural analogs in bilayer membranes.

Authors:  Michael W Maddox; Marjorie L Longo
Journal:  Biophys J       Date:  2002-12       Impact factor: 4.033

Review 3.  The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Authors:  Marinieve Montero; Nienke E van Houten; Xin Wang; Jamie K Scott
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

Review 4.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

5.  Effect of the N-terminal glycine on the secondary structure, orientation, and interaction of the influenza hemagglutinin fusion peptide with lipid bilayers.

Authors:  C Gray; S A Tatulian; S A Wharton; L K Tamm
Journal:  Biophys J       Date:  1996-05       Impact factor: 4.033

Review 6.  HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation.

Authors:  Mary Ann Checkley; Benjamin G Luttge; Eric O Freed
Journal:  J Mol Biol       Date:  2011-07-22       Impact factor: 5.469

7.  HIV fusion peptide penetrates, disorders, and softens T-cell membrane mimics.

Authors:  Stephanie Tristram-Nagle; Rob Chan; Edgar Kooijman; Pradeep Uppamoochikkal; Wei Qiang; David P Weliky; John F Nagle
Journal:  J Mol Biol       Date:  2010-07-22       Impact factor: 5.469

8.  A peptide analogue to a fusion domain within photoreceptor peripherin/rds promotes membrane adhesion and depolarization.

Authors:  K Boesze-Battaglia; F P Stefano; M Fenner; A A Napoli
Journal:  Biochim Biophys Acta       Date:  2000-02-15

9.  Specificity of amphiphilic anionic peptides for fusion of phospholipid vesicles.

Authors:  M Murata; S Takahashi; Y Shirai; S Kagiwada; R Hishida; S Ohnishi
Journal:  Biophys J       Date:  1993-03       Impact factor: 4.033

10.  Correlation between fusogenicity of synthetic modified peptides corresponding to the NH2-terminal extremity of simian immunodeficiency virus gp32 and their mode of insertion into the lipid bilayer: an infrared spectroscopy study.

Authors:  I Martin; M C Dubois; F Defrise-Quertain; T Saermark; A Burny; R Brasseur; J M Ruysschaert
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.